Discharge Readmission Analysis and Management in Sepsis (DReAMS-2) - Trial NCT06099756
Access comprehensive clinical trial information for NCT06099756 through Pure Global AI's free database. This phase not specified trial is sponsored by Measure Labs, Inc. and is currently Recruiting. The study focuses on Sepsis. Target enrollment is 2000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Measure Labs, Inc.
Timeline & Enrollment
N/A
Oct 26, 2023
Oct 01, 2024
Primary Outcome
Unplanned readmissions
Summary
This is an adaptive platform. This study is being done to collect information that will help
 us identify trends in patients with sepsis and other health conditions being readmitted into
 hospitals within 30 days of being discharged. This information will be used to create a
 computer tool that will help predict a patient's risk of being readmitted into the hospital
 after being discharged.
 
 Participants will allow the study team to follow their health after they are discharged by
 taking their temperature once a day and placing their index finger over their smartphone
 camera when prompted by a text message. Participants will receive the text messages twice a
 day. When the participant receives the text message, they will click on the link and follow
 the instructions. Instructions include how to long to keep your finger on your phone camera
 and how to report your daily temperature. Additional questions will also be asked. After 30
 days, the text messages will stop, and participation will be complete.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06099756
Non-Device Trial